If you want a Stock Review on ATRS, IART, BDX, or WAT then come over to http://dailystocktracker.com/register/ and …
Moreover, Blackrock Advsr Limited Company has 0% invested in Antares Pharma Inc (NASDAQ:ATRS) for 26,095 shares ... Retirement Systems invested in 817,000 shares or 0% of the stock. The Return on Investment (ROI) ratio of Antares …
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that data from the 52 week phase ... Register now to create …
Prior to April 16, Antares shares had been riding an upward wave on the charts. This trend has since turned upside down and ATRS stock has, as a result, lost roughly 30 per cent of its market value. If the 8-K from that same day is anything …
Antares Pharma Inc. was a big mover last session, as the company saw its shares rise more than 10% on the day. Shares moved up after the company along with Teva Pharmaceutical Industries Ltd announced the launch of the generic …
Sign-up for a FREE trial here. H.C. Wainwright initiates coverage on Antares Pharma (NASDAQ: ATRS) with a Buy rating and a price target of $5.00. Analyst Corey Davis notes while the stock has rebounded strongly off multi-year lows, they …
In related news, CEO Robert F. Apple sold 40,000 shares of the company's stock in a transaction on Wednesday, April 5th. It also reduced 3M Company (NYSE:MMM) stake by 7,000 shares and now owns 37,791 shares. Oxford Asset …
An investor must check the following items in an income statement: Topline: A growing topline ... One needs to compare the QoQ or YoY topline growth of ATRS stock with its peers like ATRI stock and BRLI stock to see if the growth …
The Target Price for Antares Pharma Cmn (NASDAQ:ATRS) is $4.58/share according to the consensus analysis of analysts working on the stock. If you are accessing this report on another domain, it was illegally copied and reposted …
Many analysts are providing their Estimated Earnings analysis for Antares Pharma Inc. and for the current quarter 5 analysts have projected that the stock could give an Average Earnings estimate of $-0.03/share. These analysts have …